ExodusPoint Capital Management LP Takes $1.14 Million Position in Astrana Health, Inc. (NASDAQ:ASTH)

ExodusPoint Capital Management LP bought a new position in shares of Astrana Health, Inc. (NASDAQ:ASTH - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 36,150 shares of the company's stock, valued at approximately $1,140,000. ExodusPoint Capital Management LP owned approximately 0.06% of Astrana Health as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the business. Vanguard Group Inc. increased its position in shares of Astrana Health by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 4,685,959 shares of the company's stock worth $147,748,000 after acquiring an additional 20,757 shares in the last quarter. State Street Corp acquired a new position in Astrana Health in the 3rd quarter worth $91,966,000. Geode Capital Management LLC bought a new position in Astrana Health during the 3rd quarter worth about $58,995,000. Charles Schwab Investment Management Inc. increased its holdings in Astrana Health by 5.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 471,329 shares of the company's stock worth $14,861,000 after purchasing an additional 23,533 shares in the last quarter. Finally, Royce & Associates LP raised its stake in shares of Astrana Health by 122.3% in the 4th quarter. Royce & Associates LP now owns 255,552 shares of the company's stock valued at $8,058,000 after purchasing an additional 140,584 shares during the period. 52.77% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ASTH has been the subject of a number of research reports. Truist Financial decreased their price objective on Astrana Health from $50.00 to $46.00 and set a "buy" rating for the company in a report on Tuesday, March 18th. Macquarie raised shares of Astrana Health to a "hold" rating in a research note on Monday, December 16th. Robert W. Baird lowered their price objective on shares of Astrana Health from $86.00 to $50.00 and set an "outperform" rating on the stock in a report on Monday, March 3rd. Stifel Nicolaus reduced their target price on shares of Astrana Health from $70.00 to $56.00 and set a "buy" rating for the company in a report on Thursday, February 20th. Finally, Bank of America lowered their price target on shares of Astrana Health from $55.00 to $49.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $53.29.

Astrana Health Stock Down 2.9 %

ASTH traded down $0.98 during trading on Tuesday, reaching $33.07. 58,474 shares of the stock were exchanged, compared to its average volume of 270,909. The stock has a market cap of $1.66 billion, a P/E ratio of 25.36, a price-to-earnings-growth ratio of 1.37 and a beta of 1.04. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. The stock's 50 day moving average price is $32.35 and its two-hundred day moving average price is $39.76. Astrana Health, Inc. has a twelve month low of $23.12 and a twelve month high of $63.20.

Astrana Health (NASDAQ:ASTH - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.37). Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The firm had revenue of $665.21 million for the quarter, compared to analyst estimates of $617.24 million. Equities analysts expect that Astrana Health, Inc. will post 1.15 EPS for the current year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.